“`html
MetLife, Inc. (MET) has launched a Cancer Support benefit as part of its Critical Illness Insurance offering, effective January 1, 2026. This new benefit, developed in collaboration with Private Health Management, will provide employees with access to oncology experts, care coordination tools, and patient counseling services.
Employers utilizing this program have reported reductions in average treatment costs, fewer unnecessary procedures, and improved late-stage cancer survival rates. MET’s Group Benefits premiums increased by 2.2% year-over-year in the first half of 2025, suggesting potential growth in customer engagement with the new offering.
MetLife’s shares have risen 2.3% over the past three months, compared to the insurance industry growth of 1.1%. The company’s stock currently holds a Zacks Rank of #3 (Hold).
“`
